Research Peptides Explained: What “Research Use Only” Actually Means

Every product in the Wednesday catalog carries the phrase “for research use only,” and almost every customer has wondered what it commits either party to. The phrase is often treated as boilerplate, but it sits at the intersection of several distinct regulatory ideas: a labeling convention borrowed from laboratory diagnostics, the statutory definition of a drug, the doctrine of intended use, and the practical realities of an enforcement system that judges sellers by what they say and do rather than by what they print on a vial. This note explains each of those ideas as they exist in US law and FDA practice as of 2026. It is descriptive, not advisory; it does not tell anyone what they may or may not do, and it is not legal advice. Readers with specific compliance questions should consult counsel.

Where the phrase comes from

“For research use only” has a precise home in US regulation, and it is not peptides. Under 21 CFR 809.10(c)(2)(i), an in vitro diagnostic product that is in the laboratory research phase of development, and is not represented as an effective diagnostic, must carry the statement “For Research Use Only. Not for use in diagnostic procedures.”¹ A companion label, “For Investigational Use Only,” covers diagnostic products being evaluated before commercial release. FDA’s 2013 guidance on the distribution of RUO and IUO products explains how the agency interprets these labels and, importantly, states that the label alone does not settle the product’s status: if a manufacturer’s marketing, customer base or technical support show the product is intended for clinical diagnostic use, FDA will treat it accordingly.²

The peptide industry adopted the wording by analogy. There is no regulation that creates an RUO category for chemical substances, and no FDA filing or registration attaches to a peptide sold under that label. What the phrase does is communicate that the seller is offering the material as a laboratory reagent for in vitro or animal research, and that it is not being offered as a drug for people. Whether that communication is credible is judged, as with diagnostics, by everything else the seller says and does.

The statutory definition of a drug

The Federal Food, Drug and Cosmetic Act defines a drug in section 201(g)(1) to include articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, and articles other than food intended to affect the structure or any function of the body.³ The key word is intended. The same molecule can be a drug or not a drug depending on the purpose for which it is offered. A bottle of sodium chloride sold as a laboratory reagent is a chemical; the same salt in a bag labeled for intravenous infusion is a drug.

Section 201(p) defines a new drug as one not generally recognized among qualified experts as safe and effective for its labeled uses, and section 505(a) prohibits introducing a new drug into interstate commerce without an approved application.³ Section 301(d) makes such introduction a prohibited act. Nearly every peptide sold as a research chemical would meet the definition of a new drug if it were intended for human use, because none has an approved application for the form in which it is sold. This is true even of peptides that exist as approved drugs in other forms: a research-grade GLP-1 analogue is not the approved pharmaceutical product, has not been manufactured under the approved application, and carries none of the assurances that application provides.

Intended use: how FDA decides

The regulation that governs how FDA determines intended use is 21 CFR 201.128, amended in a final rule published in August 2021.⁴ It states that intended use is determined by the objective intent of the persons legally responsible for labeling, and that this intent may be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. It may also be shown by the circumstances surrounding distribution, including the design and composition of the product and the market to which it is offered. The 2021 rule clarified that knowledge alone that a product is being used off-label does not, by itself, establish a new intended use, but it preserved the principle that FDA may consider any relevant source of evidence.⁴

The practical meaning is that a disclaimer cannot override the surrounding evidence. If a seller labels a peptide “not for human consumption” but describes on its website what the peptide does in people, presents it in injectable format with dosing information, or promotes user results, FDA will look at the whole picture. This is not a novel position; it is how FDA has applied the intended-use doctrine to dietary supplements, cosmetics, and devices for decades.

What FDA has actually said about research peptide sellers

FDA has issued a series of warning letters to online peptide sellers, and the letters are the clearest primary source on how the agency views the category. A December 2024 letter to a company selling several GLP-1-class peptides stated that despite product labeling marketing the products as “research use only” and “intended as a research chemical only,” evidence from the company’s websites established that the products were intended to be drugs for human use. The evidence cited was the company’s own descriptions of what the compounds do in people, together with social-media posts promoting outcomes.⁵ The letter cited sections 505(a) and 301(d) of the Act.

An August 2026 letter to another seller followed the same structure and cited a broader range of products, including a growth-hormone-releasing analogue and a mitochondrial peptide, alongside the reconstitution water sold with them. FDA again wrote that despite “research use only” and “not for human consumption” statements, the website established that the products were intended as drugs for human use, pointing to disease- and function-related claims on product pages and to the presentation of the products for injection.⁶

Two features of these letters are worth noting. First, FDA did not assert that selling a peptide as a laboratory chemical is itself unlawful; the letters turn on the marketing content. Second, the letters are addressed to sellers, not purchasers. The regulatory obligation described in them falls on the party introducing the product into commerce and making claims about it.

The compounding question is a separate one

A different strand of FDA activity is often confused with the research-chemical question. Under section 503A of the Act, licensed pharmacies may compound drugs for individual patients from bulk substances that meet certain criteria, one of which is appearing on a list FDA develops through rulemaking. While that list is being built, FDA has operated an interim policy that sorts nominated substances into categories. Category 1 substances may be compounded under enforcement discretion; Category 2 substances are those FDA has identified as raising significant safety risks.⁷

In September 2023 FDA placed a number of peptides in Category 2, including BPC-157, CJC-1295, ipamorelin, GHK-Cu (injectable), MOTS-c, Semax and a thymosin beta-4 fragment. In April 2026 FDA moved twelve of these peptides out of Category 2, and at a Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026, the committee voted in favor of adding six of them, including BPC-157, TB-500, MOTS-c and Semax, to the 503A bulks list.^7,8 The vote is advisory; FDA must complete rulemaking before any change takes legal effect, and it has not done so as of this writing.

None of this bears directly on research chemicals. The 503A framework governs what a licensed pharmacy may compound for a patient under a prescription. It does not create a pathway for a chemical supplier to sell peptides for human use, and a substance’s presence on or absence from the bulks list does not change the status of material sold as a laboratory reagent.

Framework	Who it governs	What it decides	Effect on research-grade peptides
FD&C Act §201(g), §505(a); 21 CFR 201.128	Anyone introducing an article into commerce	Whether the article is a drug, based on intended use	Determines whether a seller’s marketing makes the product an unapproved drug
21 CFR 809.10(c)(2)	Manufacturers of in vitro diagnostics	Required RUO/IUO labeling for diagnostics in development	Source of the borrowed phrase; does not apply to peptides directly
FD&C Act §503A and interim bulks categories	Licensed compounding pharmacies	Which bulk substances may be compounded for patients	None; governs pharmacy compounding, not chemical supply
WADA Prohibited List	Athletes subject to anti-doping rules	Which substances are prohibited in sport	Several research peptides are listed under S0 (non-approved substances) or S2

Anti-doping is another distinct regime

For completeness: the World Anti-Doping Agency’s Prohibited List includes a catch-all class, S0, covering pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use. BPC-157 was explicitly named as an example in the 2022 list, and the US Anti-Doping Agency has published guidance to athletes about it.⁹ Growth-hormone secretagogues and releasing factors fall under S2. These rules apply to athletes in tested sport and are enforced by sporting bodies, not by FDA, but they are part of the regulatory landscape around these molecules.

Why suppliers require researcher affirmations

Because intended use is assessed from the totality of circumstances, the character of a seller’s customer base and the representations made at the point of sale are part of the evidence. A supplier that sells only to purchasers who affirm they are acquiring material for laboratory research, that declines orders inconsistent with that purpose, and that confines its product descriptions to chemical identity and the published literature is building a record that its products are offered as reagents. A supplier that does none of these things has a weaker record regardless of what its labels say.

The affirmation therefore serves several functions. It documents the purchaser’s stated purpose. It puts the purchaser on notice that the material is not offered for human use and has not been evaluated for it. And it defines the terms of the transaction in a way that aligns with the seller’s stated intended use. What it does not do is transform the legal status of the material or authorize any particular use; an affirmation is a statement of purpose, not a license. FDA’s warning letters make clear that a seller cannot rely on an affirmation or disclaimer if its own marketing contradicts it.^5,6

What this framing asks of a supplier

The regulatory logic described above shapes how a research-chemical supplier can responsibly present its products. Descriptions should identify the compound, its sequence, its purity and identity data, and the published research in which it has been studied, with clear separation between preclinical and clinical evidence. They should not describe effects in people as if the product produced them, provide dosing or administration guidance, or suggest that the material treats or improves anything. Wednesday’s catalog guide and the notes in this library are written to that standard: they summarize what studies observed in the models used, they name the models, and they stop there.

The distinction is not a formality. It is the difference between a chemical supplier and an unlicensed drug seller as FDA has defined that difference in its own enforcement letters. The research-use-only framing works only when it is true.

Frequently asked questions

What does “research use only” mean on a peptide?

It means the seller is offering the material as a laboratory chemical for in vitro or animal research and not as a drug for human use. The phrase is borrowed from FDA’s labeling rules for in vitro diagnostics. It is not an FDA approval, registration or product category, and it does not by itself determine the product’s legal status.

Are research peptides FDA approved?

No. Peptides sold as research chemicals have not been reviewed by FDA for safety, efficacy or manufacturing quality. Some peptides exist as approved drugs in other forms, but research-grade material is not the approved product and has not been made under the approved application.

Why does FDA send warning letters to peptide sellers?

The letters FDA has published turn on marketing content. When a seller describes what a peptide does in people, presents it for injection, or promotes user results, FDA has concluded that the product is intended as a drug for human use despite “research only” labels, and has cited the seller under the unapproved-new-drug provisions of the Food, Drug and Cosmetic Act.

Why do peptide suppliers make you confirm you are a researcher?

Because FDA determines a product’s intended use from the total circumstances of its sale, including the customer base and the representations made at purchase. A researcher affirmation documents the purpose of the transaction and aligns it with the seller’s stated intended use. It does not change the legal status of the material or authorize any particular use.

Does the FDA compounding list change whether a peptide is legal to buy for research?

No. The 503A bulks list and its interim categories govern what licensed pharmacies may compound for patients. Moving a peptide between categories, or an advisory committee vote about it, does not affect material sold as a laboratory reagent one way or the other.

References & further reading

1. 21 CFR §809.10, Labeling for in vitro diagnostic products. Electronic Code of Federal Regulations. ecfr.gov
2. US Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and FDA Staff. November 2013. fda.gov / Federal Register notice
3. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §321(g)(1) and (p) (definitions of drug and new drug); §355(a) (new drug approval); §331(d) (prohibited acts). uscode.house.gov
4. US Food and Drug Administration. Regulations Regarding “Intended Uses”; Final Rule. Federal Register. 2021;86:41383. Codified at 21 CFR §201.128. federalregister.gov / ecfr.gov
5. US Food and Drug Administration. Warning Letter to Summit Research Peptides, MARCS-CMS 695607. 10 December 2024. fda.gov
6. US Food and Drug Administration. Warning Letter to Peak Performance Peptides, MARCS-CMS 735127. 24 August 2026. fda.gov
7. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Human Drug Compounding. fda.gov
8. US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory Committee Calendar. fda.gov
9. US Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes. Spirit of Sport. usada.org / World Anti-Doping Agency. WADA’s 2022 Prohibited List now in force. wada-ama.org